Bachem AG DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

Corporate Presentation

Scaling Up: Major Investments in Peptide Production 2025

The Online Peptide Guide 2025

Oligonucleotide Generics 2025

Oligonucleotide Therapeutics 2025

SwissMedic GMP 2024

Goserelin Leuprorelin Triptorelin 2025

Pioneering Sustainable, Large-Scale Tides Manufacturing

Maintaining a Resilient Tides Supply Chain Under VUCA Conditions

Leading the Octreotide Scale-up

Scientific Expertise to Spring 2024 Conferences

Commerical Peptide NCE

Quality Grade Building Blocks

Innovations for Tides 2024

GMP Certificate 2023

Gorerelin Leuprorelin Triptorelin 2024

Commercial Peptide NCE 2024

Molecular Hiving™ Technology

Semaglutide 2024

Lanreotide

Back to Stirred Vessels & On to Metric Tons of Oligonucleotides

Increasing Sustainability in Large Scale Peptide API Purification

Solid Phase Peptide Synthesis 2023

Purification- A Bottleneck for Oligonucleotide API Manufacturing

Click the button for full data set

Acylated Peptide Synthesis- An Analysis of Cost & Capacity

Assess and Reduce Nitrosamine Contamination Risks in Peptide APIs

Avoiding Epimerization in Peptide Synthesis

Development for Novel Peptides: Column Screening to GMP Releases

Going Large-scale with Manufacturing of Oligonucleotides

Large-scale TIDES purification with MCSGP under GMP

Learn About Methods for Making Long and Complex Peptides

Mitigating Supply Chain Risks in an Age of Disruption

More Than White Powder and Reports

Navigating Regulatory Affairs Challenges for Successful Drugs

Peptide Aggregation – A Complex Topic

Regulatory Perspective- Expectations for Peptide Therapeutics

Scalable Oligonucleotide Manufacture With Stirred-bed Technology

Tag-assisted One-pot Liquid-phase Oligonucleotide Synthesis

Expert Round – Upscaling TIDES Manufacturing 2024

New Trends in Oligotherapeutics

2nd Generation Process for the Manufacturing of Liraglutide

Innovation for Peptide & Oligonucleotide Manufacturing

Peptide-based In Vitro Diagnostics

Generic APIs-Liraglutide & Other GLP-1 Analogues

Oligonucleotide Facility Virtual Tour

Semaglutide

Leading by Experience in Generic API

Customer Testimonial

Continuous Chromatography of Peptides

Expanding into Oligos - Interview

Thiazine Formation: Elucidation of Thiol-Maleimide Side-Reaction

Oligonucleotides - Innovation that Transforms Lives

Interview with Torsten Wohr

The Perfect Ingredients for a Better World

Sherpany and Futurae

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025.

Impressions: 2992

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 3677

FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big

In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molecules. Oligonucleotides are essentially short, single strands of DNA or RNA that modulate gene expression. There are various oligonucleotide therapy (ONT) agents (such as antisense, deoxyribozymes, siRNA and CRISPR/Cas) that offer promising therapeutic tools.A variation of gene therapy, oligonucleotide gene therapies (OGTs) are manufactured using synthetic oligonucleotides. These therapies are designed to enter cells. ONTs act like tools that can fine-tune the behavior of certain genetic instructions, and are therefore often designed to treat rare and genetic diseases and cancers. Sometimes, they may be delivered into cells through lipid nanoparticles or adeno-associated viruses (AAV), halting the translation of a specific protein. Oligonucleotides have also revolutionized vaccine development through the creation of nucleic acid vaccines, such as mRNA vaccines.The first oligonucleotide drug, known as fomivirsen, was approved by the US Food and Drug Administration (FDA) back in 1998. It was developed by Ionis Pharmaceuticals (then known as Isis Pharmaceuticals), and was approved to treat a rare eye disease. However, ONT approvals have picked up since 2016. Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency (EMA) and a majority of them treat orphan and rare diseases.In 2023, FDA approved four ONTs — AstraZeneca-Ionis’ Wainua (eplontersen), Novo Nordisk owned Dicerna Pharmaceuticals’ Rivfloza (nedosiran), Biogen-Ionis’ Qalsody (tofersen) and Iveric Bio’s Izervay (avacincaptad pegol).In 2021, the global ONT market size was estimated to be US$ 18.2 billion. It is expected to increase to US$ 51.4 billion by 2029, growing at a compounded annual rate (CAGR) of 13.85 percent. Similarly, the market for oligonucleotides synthesis (or the process of producing oligonucleotides) was estimated at US$ 7.7 billion globally in 2022 and is expected to grow 11.8 percent CAGR to reach US$ 16.4 billion by 2030. Some of the bigger players in oligonucleotides synthesis are Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins, Agilent, Bio-Synthesis, EUROAPI, Eurogentec, STA Pharma, and Bachem.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available)ONTs address neuro disorders; four ONTs bring in US$ 1.24 bn for AlnylamONTs are widely applied to treat neurodegenerative diseases, such as Duchenne muscular dystrophy (DMD). Multiple ONTs have been approved in Europe and the US for DMD, such as Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Amondys 45 (casimersen) from Sarepta and NS Pharma’s Viltepso (viltolarsen). Last year, Ionis bagged two approvals in the space. FDA approved its Biogen-partnered therapy Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS). The agency also approved AstraZeneca and Ionis’ drug Wainua (eplontersen), rendering it as the first self-administered treatment for a rare nerve damage disease, known as hereditary transthyretin amyloidosis (ATTR-PN). Analysts estimate global peak sales for Wainua to come in at US$ 750 million for ATTR-PN alone. The drug is also being tested for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare heart muscle disorder.Alnylam Pharmaceuticals has also successfully brought four ONTs to market in recent years — Onpattro (patisiran) and Amvuttra (vutrisiran) for rare nerve diseases, and Givlaari (givosiran) and Oxlumo (lumasiran). Givlaari has been approved to treat acute hepatic porphyria (a liver enzyme deficiency) while Oxlumo treats primary hyperoxaluria (a disorder characterized by increased urinary oxalate excretion). The four ONTs brought in US$ 1.24 billion for Alnylam in 2023.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Novartis buys rights to siRNA therapy, GSK bets big on ONT pipeline through dealsAfter Alnylam discovered inclisiran (Leqvio), Novartis acquired global rights to the therapy in a US$ 9.7 billion deal. Leqvio was the first FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction. It brought in US$ 355 million for Novartis in 2023.GSK has increasingly been investing in its ONT pipeline. The British pharma has promised over US$ 5 billion in upfront and milestone payments in multiple deals. In February, GSK exercised its option to license Elsie Biotechnologies’ discovery platform to find and develop novel ONTs. GSK has also entered a discovery collaboration with Wave Life Sciences.Last July, Japanese drugmaker Astellas Pharma completed its approximately US$ 5.9 billion buyout of New Jersey-headquartered Iveric Bio. Iveric focuses on retinal diseases and the deal gives Astellas drug candidates to treat about 160 million people with eye ailments. Subsequently, in August, Iveric’s Izervay (avacincaptad pegol) was approved by the FDA as a new treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).After Novo Nordisk acquired RNAi technology company Dicerna Pharmaceuticals for US$ 3.3 billion in 2021, the latter’s once-monthly RNAi therapy Rivfloza (nedosiran) saw FDA approval last October. Rivfloza was okayed for children nine years and older to treat a rare genetic condition that affects the kidneys, known as primary hyperoxaluria type 1 (PH1).View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Ionis tees up NDAs for rare disease treatments after two late-stage trial winsThe industry is looking for cures to a wide spectrum of diseases like cancer (such as melanoma, pancreatic, liver, glioblastoma, breast and ovarian cancer), cystic fibrosis, Alzheimer’s disease, Parkinson’s disease, hepatitis B, asthma, Rett syndrome, non-alcoholic steatohepatitis, and IgA nephropathy through its research on ONTs.In January, Ionis announced late-stage results wherein its RNA-targeted hereditary angioedema (HAE) candidate, donidalorsen, significantly reduced the rate of HAE attacks in patients treated every four weeks and patients treated every eight weeks. The California-based biotech is readying a new drug application (NDA) to submit to the FDA. HAE is a rare and life-threatening genetic disease that causes unpredictable and frequent severe swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat. This year, Ionis’ olezarsen was granted fast track designation by the FDA for the rare genetic disease familial chylomicronemia syndrome (FCS). Last September, olezarsen had met its primary endpoint of reducing abnormally high levels of triglycerides in a late-stage trial in patients with the metabolic disorder. Currently, there are no FDA-approved treatments for this condition. If okayed, olezarsen is likely to bring in US $849 million in sales for Ionis by 2032.In March, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in certain adult patients with myelodysplastic syndromes. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024, for Geron’s NDA for imetelstat. It is among the most anticipated drug launches this year.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Our viewDeveloping ONTs is a field fraught with challenges, such as toxicity and drug delivery. There are safety concerns as well as concerns around delivering the therapy. However, technological breakthroughs and collaborations between pharma firms and contract research organizations that focus on drug delivery are continuously working towards addressing these challenges. All in all, we foresee exciting times ahead for ONTs.

Impressions: 4293

NEWS #PharmaBuzz

Efficient project management in pharma: 8 steps to optimize

30 Apr 2025

// EXPRESSPHARMA

Inside Manufacturing at Bachem – A Day with Ronja Otter

13 Jan 2025

// PRESS RELEASE

How to Choose the Right CDMO Partner: Key Factors to Consider

20 Nov 2024

// PRESS RELEASE

Bachem’s Sustainable TIDES Manufacturing

30 Oct 2024

// PRESS RELEASE

Bachem at Swiss Technology Award 2024

20 Sep 2024

// PRESS RELEASE

Bachem Reports Slight H1 2024 Sales Growth And Confirms Full-Year Outlook

25 Jul 2024

// PRESS RELEASE

ALL APIs

01

Calcitonin

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

Click Us!

CEP/COS

JDMF

EU-WC NDC

KDMF VMF Others AUDIT

02

Carbidopa

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF Others AUDIT

03

Goserelin Acetate

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF Others AUDIT

04

Leuprolide Acetate

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF

VMF Others AUDIT

05

Octreotide Acetate

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF

EU-WC NDC

KDMF VMF Others AUDIT

06

Propofol

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF

EU-WC NDC KDMF

VMF Others AUDIT

07

Etomidate

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF EU-WC NDC

KDMF VMF Others AUDIT

08

Glucagon

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS JDMF

EU-WC NDC

KDMF VMF Others AUDIT

09

Glucagon

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS JDMF

EU-WC NDC KDMF VMF Others AUDIT

10

Gonadorelin Acetate

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

USDMF

CEP/COS

JDMF EU-WC NDC

KDMF

VMF

Others AUDIT

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY PRODUCTS

TOP RANKED SUPPLIER FOR:

Services

Discover the service capabilities from this company

Analytical

Discover their expertise for :

Analytical Method Development

01

ANALYTICAL METHOD DEVELOPMENT

Switzerland

Bachem has extensive analytical expertise and offers all analytical services to ensure successful product development. Its GMP-compliant analytical capabilities include method development and validation, stability studies, nitrosamine determination, etc.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : Analytical

Bachem AG

Category : Analytical Method Development

Sub Category : Method Development and Validation

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : Analytical

ANALYTICAL METHOD DEVELOPMENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Manufacturing

Discover their expertise for :

Scale Up

01

SCALE UP OF PEPTIDE APIs

Switzerland

Bachem produces one of the largest amounts of commercially available synthetic peptide active pharmaceutical ingredients (API) in the world. It has the capacity to produce peptide API from gram scale to annual quantities of hundreds of kilograms.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Scale Up

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

SCALE UP OF PEPTIDE APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Clinical Supply

01

CLINICAL SUPPLY OF PEPTIDE APIs

Switzerland

Bachem is the world´s leading independent manufacturer of peptide and oligonucleotide APIs. It is a CDMO that offers process development, characterization, and qualification for all phases of clinical trials and commercial supply.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Clinical Supply

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

CLINICAL SUPPLY OF PEPTIDE APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Small Molecules

01

SMALL MOLECULE API MANUFACTURING

Switzerland

Bachem is a well-established manufacturer of GMP small molecule APIs. It offers several services for small molecules including process development, chiral synthesis, hydrogenations, oxidation and reduction using various reagents & high pressure reactions.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Small Molecules

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

SMALL MOLECULE API MANUFACTURING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Chiral Synthesis

01

CHIRAL SYNTHESIS

Switzerland

Bachem CDMO has the capability to produce GMP small molecules at its site in Vionnaz. It offers several services, including chiral synthesis, process development, hydrogenation, heterocyclic chemistry, metal-catalyzed reactions, etc.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Chiral Synthesis

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

CHIRAL SYNTHESIS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GMP Manufacturing

01

GMP MANUFACTURING FOR PEPTIDE APIs

Switzerland

Bachem is a CDMO with its manufacturing facilities complying with Good Manufacturing Practice (GMP) standards of regulatory agencies, such as the Food and Drug Administration (FDA) and the Swissmedic (Switzerland).

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : GMP Manufacturing

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

GMP MANUFACTURING FOR PEPTIDE APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Custom Synthesis & Manufacturing

01

PEPTIDE CUSTOM SYNTHESIS & MANUFACTURING

Switzerland

Bachem offers customized, high-quality, reliable, flexible and cost-effective solutions to peptide synthesis. It has the capability to synthesize peptides at different purity levels (crude to ≥ 97%) and scales (mg to kg).

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Custom Synthesis & Manufacturing

Sub Category : Custom Synthesis

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

PEPTIDE CUSTOM SYNTHESIS & MANUFACTURING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Oligonucleotide / Polynucleotide

01

CMO FOR OLIGONUCLEOTIDE APIs

Switzerland

Bachem has over 50 years of experience in the contract development and manufacturing of oligonucleotides, amino acids, complex organic molecules, and biologically active peptides as active pharmaceutical ingredients (APIs).

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Oligonucleotide / Polynucleotide

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

CMO FOR OLIGONUCLEOTIDE APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Protein / Peptide

01

CUSTOM PEPTIDE SYNTHESIS

Switzerland

Bachem is a contract development and manufacturing organization that has expertise in producing a variety of peptides. It has the capability to synthesize peptides at different purity levels (crude to ≥ 97%) & scales (mg to kg) with customized solutions.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Protein / Peptide

Sub Category : Synthesis

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

CUSTOM PEPTIDE SYNTHESIS

02

CMO FOR PEPTIDE & OLIGONUCLEOTIDE APIs

Switzerland

Bachem's production plants are endowed with state-of-the-art equipment for the purification and isolation of peptide and oligonucleotide APIs and intermediates. It utilizes various methods for purification including preparative HPLC, IEX, SEC, UF & TFF.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

Bachem AG

Category : Protein / Peptide

Sub Category : Overview

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API Manufacturing

CMO FOR PEPTIDE & OLIGONUCLEOTIDE APIs

Capabilities
#ServicesBio

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API & Drug Product Development

Discover their expertise for :

API Development

01

CUSTOM SYNTHESIS OF PEPTIDES

Switzerland

Bachem offers an efficient and high-quality custom synthesis for peptides and amino acid derivatives from the mg to kg scale. It offers a huge range of modifications in peptide synthesis such as N-terminal, C-terminal and backbone peptides.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API & Drug Product Development

Bachem AG

Category : API Development

Sub Category : Custom Synthesis

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API & Drug Product Development

CUSTOM SYNTHESIS OF PEPTIDES

02

CDMO FOR PEPTIDES & OLIGONUCLEOTIDES

Switzerland

Bachem has more than 50 years of experience in the development, manufacturing, and regulatory support of biologically active peptides, oligonucleotides, and complex organic molecules as active pharmaceutical ingredients (APIs).

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API & Drug Product Development

Bachem AG

Category : API Development

Sub Category : Protein / Peptide

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API & Drug Product Development

CDMO FOR PEPTIDES & OLIGONUCLEOTIDES

03

CDMO FOR OLIGONUCLEOTIDES

Switzerland

Bachem is one of the world’s largest independent oligonucleotide and peptide full-service providers specialized in the process development and manufacturing of oligonucleotides, peptides, and complex organic molecules as active pharmaceutical ingredients.

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API & Drug Product Development

Bachem AG

Category : API Development

Sub Category : Oligonucleotide / Polynucleotide

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Pharma Service : API & Drug Product Development

CDMO FOR OLIGONUCLEOTIDES

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY SERVICES

TOP RANKED SUPPLIER FOR:

Inspections and registrations

Check the inspections & registration from this company

FDA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GDUFA

01 GDUFA fees paid

USA

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Paid in : 2024

Bachem AG

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : Bachem AG

Business Address : Hauptstrasse 144 Bubendorf B...

FEI Number : 1000153019

Country : Switzerland

Paid in : 2024

Product
Web Link

02 GDUFA fees paid

USA

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Paid in : 2023

Bachem AG

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : Bachem Americas, Inc.

Business Address : 1271 Avenida Chelsea Vista C...

FEI Number : 3000718309

Country : Switzerland

Paid in : 2023

Product
Web Link

03 GDUFA fees paid

USA

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Paid in : 2018

Bachem AG

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : Bachem Americas, Inc.

Business Address : 1271 Avenida Chelsea Vista C...

FEI Number : 3012673677

Country : Switzerland

Paid in : 2018

Product
Web Link

04 GDUFA fees paid

USA

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Paid in : 2024

Bachem AG

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : Bachem Americas, Inc.

Business Address : 3132 Kashiwa Street Torrance...

FEI Number : 2024023

Country : Switzerland

Paid in : 2024

Product
Web Link

05 GDUFA fees paid

USA

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Paid in : 2024

Bachem AG

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : BACHEM SA

Business Address : Succursale de Vionnaz Route ...

FEI Number : 3002808225

Country : Switzerland

Paid in : 2024

Product
Web Link

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Others

01 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : SwissMedic GMP 2024

Country : Switzerland

Product
Web Link

02 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2015-06-17; Type- GMP Foreign

Country : Switzerland

Product
Web Link

03 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2014-11-03; Type- GMP Foreign

Country : Switzerland

Product
Web Link

04 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2014-11-03; Type- GMP Foreign

Country : Switzerland

Product
Web Link

05 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2013-01-22; Type- GMP Foreign

Country : Switzerland

Product
Web Link

06 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2012-04-24; Type- GMP Foreign

Country : Switzerland

Product
Web Link

07 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2012-04-16; Type- GMP Foreign

Country : Switzerland

Product
Web Link

08 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : Health Canada: Inspection Start Date: 2012-01-09; Type- GMP Foreign

Country : Switzerland

Product
Web Link

09 Inspected

RoW

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

Inspection : SwissMedic GDP 2024

Country : Switzerland

Product
Web Link